Hostname: page-component-669899f699-7xsfk Total loading time: 0 Render date: 2025-05-05T23:06:34.476Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al

Published online by Cambridge University Press:  11 December 2024

Gero Joks Open the ORCID record for Gero Joks [Opens in a new window] ,
Steve Su  and
Jarrad King
Gero Joks
Affiliation:
Medical & Scientific Affairs, Janssen-Cilag Pty Ltd, Sydney, Australia
Steve Su
Affiliation:
Integrated Market Access, Janssen-Cilag Pty Ltd, Sydney, Australia
Jarrad King*
Affiliation:
Medical & Scientific Affairs, Janssen-Cilag Pty Ltd, Sydney, Australia
*
Correspondence: Jarrad King. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Regarding the article, ‘Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial’, we commend Loo et al1 for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare professionals on treatment-resistant depression, we raise several points herein to help clarify and provide additional perspective to the researchers’ interpretation of their findings in the Discussion.

Keywords

Esketamineketaminemajor depressive disorderdepression
Type
Commentary
Information
The British Journal of Psychiatry , Volume 225 , Issue 5 , November 2024 , pp. 515 - 516
Check for updates
Copyright
Copyright © Janssen-Cilag Pty Limited, 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Loo, C, Glozier, N, Barton, D, Baune, BT, Mills, NT, Fitzgerald, P, et al. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial. Br J Psychiatry 2023; 223(6): 533–41.CrossRefGoogle ScholarPubMed
Phillippo, DM, Ades, AE, Dias, S, Palmer, S, Abrams, KR, Welton, NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making 2018; 38(2): 200–11.CrossRefGoogle ScholarPubMed
Popova, V, Daly, EJ, Trivedi, M, Cooper, K, Lane, R, Lim, P, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428–38.CrossRefGoogle ScholarPubMed
Bahji, A, Vazquez, GH, Zarate, CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021; 278: 542–55.CrossRefGoogle ScholarPubMed
Drevets, WC, Popova, V, Daly, EJ, Borentain, S, Lane, R, Cepeda, MS, et al. Related comments in: Ekstrand J. Letter to the Editor. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord 2021; 289: 88–9. Related comments in: Souza-Marques B, Mello RP, Jesus-Nunes AP, Correia-Melo FS, Sampaio AS, Quarantini LC. Letter to the editor - Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord 2021; 283: 265–66.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.